CAMG Solamere Management LLC grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 29.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,085 shares of the medical instruments supplier’s stock after acquiring an additional 930 shares during the period. CAMG Solamere Management LLC’s holdings in Becton Dickinson and were worth $887,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. Amica Retiree Medical Trust grew its stake in shares of Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after acquiring an additional 390 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and in the fourth quarter worth $109,000. Advisors Preferred LLC acquired a new position in shares of Becton Dickinson and in the fourth quarter worth $126,000. Truewealth LLC acquired a new position in shares of Becton Dickinson and in the fourth quarter worth $133,000. Finally, Penserra Capital Management LLC acquired a new position in shares of Becton Dickinson and in the fourth quarter worth $136,000. Institutional investors and hedge funds own 84.26% of the company’s stock.
In related news, EVP Nabil Shabshab sold 10,209 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $226.10, for a total value of $2,308,254.90. Following the completion of the sale, the executive vice president now directly owns 12,476 shares of the company’s stock, valued at $2,820,823.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexandre Conroy sold 20,128 shares of the business’s stock in a transaction on Monday, May 21st. The shares were sold at an average price of $228.74, for a total transaction of $4,604,078.72. Following the completion of the sale, the insider now directly owns 35,583 shares of the company’s stock, valued at $8,139,255.42. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.
BDX has been the subject of several research reports. ValuEngine upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Citigroup upgraded shares of Becton Dickinson and from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $237.00 to $251.00 in a research note on Tuesday, April 10th. Finally, BMO Capital Markets initiated coverage on shares of Becton Dickinson and in a research note on Monday, March 5th. They issued a “market perform” rating and a $249.00 price target for the company. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $241.19.
Becton Dickinson and opened at $232.82 on Friday, MarketBeat reports. The firm has a market cap of $62.06 billion, a PE ratio of 24.56, a PEG ratio of 1.62 and a beta of 1.12. Becton Dickinson and Co has a 12-month low of $190.60 and a 12-month high of $248.39. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.70 and a quick ratio of 1.12.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.02. The business had revenue of $4.22 billion during the quarter, compared to analysts’ expectations of $4.12 billion. Becton Dickinson and had a negative net margin of 0.46% and a positive return on equity of 14.27%. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.30 EPS. sell-side analysts forecast that Becton Dickinson and Co will post 10.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, June 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.29%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 31.65%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.